Kidney international最新文献

{"title":"Triggering trouble: post-translational modifications may drive myeloperoxidase autoimmunity.","authors":"Peter Heeringa,Abraham Rutgers","doi":"10.1016/j.kint.2025.05.024","DOIUrl":"https://doi.org/10.1016/j.kint.2025.05.024","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"29 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144630355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iohexol clearance, but not estimated GFR, reveals a steeper GFR decline in patients with prediabetes.","authors":"Toralf Melsom,Karl Marius Brobak,Jon Viljar Norvik,Inger Therese Enoksen,Ludvig Rinde,Trond G Jenssen,Bjørn O Eriksen","doi":"10.1016/j.kint.2025.06.019","DOIUrl":"https://doi.org/10.1016/j.kint.2025.06.019","url":null,"abstract":"INTRODUCTIONPrediabetes, an intermediate state between normoglycemia and type 2 diabetes affecting 720 million individuals worldwide, is associated with hyperfiltration, an early stage of diabetic kidney disease. It remains unclear whether prediabetes is an independent risk factor for glomerular filtration rate (GFR) decline, potentially due to previously inaccurate GFR estimates.METHODSIn a prospective study of middle-aged Europeans without diabetes, cardiovascular disease, or kidney disease, we measured the GFR (mGFR) using iohexol clearance at baseline (1594 individuals), after a median of 5.2-6.0 years (1299 individuals), and 11.0 years (1151 individuals). A linear mixed model was used to estimate the mGFR slope. Accelerated mGFR decline was defined as the participants with the 10% steepest mGFR decline. We also estimated GFR (eGFR) from creatinine (eGFRcrea) and cystatin C (eGFRcys). Prediabetes was defined as fasting glucose of 6.1-6.9 mmol/l (prediabetes World Health Organization (WHO)) or 5.6- 6.9 mmol/l and/or HbA1c 5.7-6.4% (39 - 46 mmol/mol) (prediabetes American Diabetes Association (ADA)).RESULTSIn adjusted linear mixed models, those with prediabetesWHO and those with prediabetesADA had steeper mean mGFR decline rates of 0.30 (95% confidence interval: 0.04 to 0.57) and (0.14 to 0.28) mL/min per year, respectively. The odds ratios of accelerated GFR decline were 2.6 (2.0-5.1) for prediabetesWHO and 2.0 (1.3-3.0) for prediabetesADA. Significantly, prediabetes was not associated with eGFRcrea or eGFRcys decline.CONCLUSIONSIn a representative sample of Caucasians without diabetes, prediabetes was associated with an accelerated mGFR decline but not with eGFR decline. Prediabetes represents a window of opportunity to prevent hyperfiltration and early mGFR loss before diabetic kidney disease.","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"23 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phosphoenolpyruvate carboxykinase 1-mediated cataplerosis is required to maintain mitochondrial fitness and to avoid kidney disease progression.","authors":"Delal Dalga,Anna Rinaldi,Xiaorong Fu,Lucie Chanvillard,Aurelie Huber,Anna Faivre,David Jaques,Lena Berchtold,Julien Boccard,Gregoire Arnoux,Arnaud Lyon,Joseph M Rutkowski,Quentin Gex,Deborah Paolucci,Mario Kreuzfeld,Thomas Cagarelli,Lea Lutz,Alban Longchamp,Solange Moll,Nicolas Hulo,Belen Ponte,Shawn C Burgess,Pietro E Cippà,Thomas Verissimo,Sophie de Seigneux","doi":"10.1016/j.kint.2025.06.018","DOIUrl":"https://doi.org/10.1016/j.kint.2025.06.018","url":null,"abstract":"INTRODUCTIONMetabolic alterations are recognized as key features of kidney injury, but their causal role in kidney repair remains debatable. Here, we investigate the role of phosphoenolpyruvate carboxykinase 1 (PCK1), an enzyme involved in gluconeogenesis and cataplerosis (removal of tricarboxylic acid (TCA) cycle intermediates from the mitochondrial matrix) in kidney disease progression.METHODSWe used mice with kidney tubular cell-specific deletion or overexpression of the PCK1 enzyme, and different models of kidney injury such as ischemia-reperfusion injury or cis-platin-induced nephropathy. Furthermore, we measured metabolites in kidney biopsy tissue from patients with stage 3b/4 chronic kidney disease (CKD).RESULTSUsing flux analysis, we confirm that cataplerosis and the TCA cycle are blocked by PCK1 deficiency. This results in injured mitochondria leading to inflammation, tubular injury and impaired tubular cell repair. Inversely, maintaining PCK1 function in different models of kidney injury preserves kidney structure, improves TCA cycle metabolite clearance and increase ATP production. In kidney biopsies from different patient cohorts, we confirm the correlation between PCK1 loss, mitochondrial injury and a failed tubular cell repair phenotype. Furthermore, in CKD, accumulation of TCA cycle metabolites is consistent with disrupted cataplerosis.CONCLUSIONSOverall, we demonstrate that PCK1 loss in kidney tubular cells leads to decreased respiration and the accumulation of TCA cycle metabolites. Maintenance of cataplerosis is an important factor of tubular physiology and repair, with PCK1 serving as a causal and potential therapeutic target in this process. PCK1 restoration enhances mitochondrial health, limiting progression to inflammation and fibrosis.","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"29 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of ceramides in the pathogenesis of atherosclerosis.","authors":"Tilman B Drueke,Ziad A Massy","doi":"10.1016/j.kint.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.kint.2025.05.020","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"7 10 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omic factor analyses uncovered cross-compartment complexity of biological processes in kidney transplantation.","authors":"Claire Tinel,Alexis Varin,Dany Anglicheau,Jasper Callemeyn,Jetty De Loor,Wilfried Gwinner,Pierre Marquet,Marion Rabant,Virginia Sauvaget,Elisabet Van Loon,Maarten Naesens,Baptiste Lamarthée","doi":"10.1016/j.kint.2025.06.017","DOIUrl":"https://doi.org/10.1016/j.kint.2025.06.017","url":null,"abstract":"INTRODUCTIONUnderstanding the complexity of pathways involved in allograft injuries after solid organ transplantation is essential for precise definitions of rejection subtypes and improved overall outcomes. High throughput technologies and the recently available computational methods make it now possible to address such complex biological questions. Here, we performed a unique compilation of six omics datasets (170,000 variables) from a multi-center study encompassing 131 kidney transplant recipients.METHODSUsing multi-omics factor analysis (MOFA), we investigated sources of variability in patient blood, urine and their allograft at the epigenetic and transcriptomic levels.RESULTSIntegrating the different omics layers, MOFA delimited eight hidden factors in an unsupervised manner. We identified specific factors that reflect allograft rejection and their multicellular complex immune profiles, complement activation, monocyte crosstalk, or immune modifications associated with induction treatment.CONCLUSIONSThese cross-compartment large datasets translated into an understandable biological picture provide a new framework to solve complex biological questions, not unique to transplant medicine.","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"28 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating estimated glomerular filtration rate and kidney replacement therapy criteria within the definition of kidney failure.","authors":"Ping Liu,Simon Sawhney,Ngan N Lam,Robert R Quinn,Christian F Christiansen,Gregory L Hundemer,Ayub Akbari,Meghan J Elliott,Tyrone G Harrison,Paul Ronksley,Helen Tam-Tham,Karthik K Tennankore,Matthew T James,Pietro Ravani","doi":"10.1016/j.kint.2025.06.015","DOIUrl":"https://doi.org/10.1016/j.kint.2025.06.015","url":null,"abstract":"INTRODUCTIONGuidelines define kidney failure based on initiation of maintenance kidney replacement therapy (KRT) or estimated glomerular filtration rate (eGFR) below 15 ml/min per 1.73 m2 for over 90 days, but most kidney failure registries track the incidence and outcomes of people who receive KRT only. The population burden of kidney failure and outcomes of patients identified by eGFR criteria remain understudied.METHODSUsing population-based datasets from Alberta, Canada, we studied adults who initiated KRT or had incident kidney failure defined by KRT or eGFR criteria between April 2008 and March 2019. Individuals who met eGFR criteria for kidney failure were followed from cohort entry until death, initiation of KRT, or censoring (outmigration or March 31, 2021) to estimate the five-year risks of KRT initiation and death without receiving KRT and the rates of acute care utilization during follow-up.RESULTSThe annual incidence was 212 per million population for KRT versus 293 for kidney failure, with larger incidence differences between KRT and kidney failure in older age and females. Among the 9691 incident kidney failure cases, 6216 (64.1%) were first identified by eGFR criteria. Within five years of meeting eGFR criteria, 34.0% died without receiving KRT. Females were less likely to receive KRT, more likely to die without receiving KRT, and had higher acute care use.CONCLUSIONSKRT registries may capture only one-third of incident kidney failure cases, inaccurately record the timing of disease onset, and under-represent older adults and females who have worse outcomes. Incorporating eGFR measurements to expand kidney failure data collection initiatives can potentially improve early disease identification, equity of healthcare planning, and outcome reporting for all affected individuals.","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"8 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis.","authors":"Steven Fishbane,Laura M Dember,Michel Jadoul,Csaba P Kovesdy,Nicolas Guzman,George Kordzakhia,Vera Lisovskaja,Priya Sekar,Peter Wessman,Ayman Al-Shurbaji,Charles A Herzog","doi":"10.1016/j.kint.2025.06.016","DOIUrl":"https://doi.org/10.1016/j.kint.2025.06.016","url":null,"abstract":"INTRODUCTIONPatients receiving maintenance hemodialysis frequently experience pre-dialysis hyperkalemia, with associated arrhythmias and cardiovascular events. The DIALIZE Outcomes trial evaluated the effect of sodium zirconium cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes.METHODSAdults receiving thrice-weekly hemodialysis with pre-dialysis hyperkalemia (serum potassium was 5.5 mmol/l or more) were randomized 1:1 to SZC (5 g once daily on non-dialysis days, then titrated weekly over four weeks between 0 and 15 grams to attain normokalemia (serum potassium 4.0-5.0 mmol/l) or placebo. The primary outcome was a composite end point of sudden cardiac death, stroke, or arrhythmia-related hospitalization, intervention, or emergency department visit. Secondary end points included individual cardiovascular outcomes from the primary composite end point, and those reflecting serum potassium control. Safety was evaluated throughout.RESULTSOverall, 2690 participants were randomized. The trial was terminated early due to low event rates (about 33% of planned) and high study medication discontinuation rates, limiting generalizability of the results. No treatment effect was observed on the primary composite end point (SZC, 8.8% [119 patients] vs. placebo, 8.9% [119 patients]; hazard ratio 0.98; 95% confidence interval 0.76-1.26) or individual cardiovascular outcomes. Maintenance of normokalemia at 12 months was significantly better with SZC than placebo (74.0% [495 patients] vs. 20 47.0% [293 patients]; odds ratio 3.36; 95% confidence interval 2.64-4.26). Serious adverse events occurred in 38.6% (SZC) and 37.6% (placebo) of participants; hypokalemia occurred in 3.0% (SZC) and 1.4% (placebo).CONCLUSIONSZC did not demonstrate a treatment effect on arrhythmia-related cardiovascular outcomes despite efficacy on serum potassium control.","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"366 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multiomic resource to interpret genetic associations with kidney function.","authors":"Pascal Schlosser, Anna Köttgen","doi":"10.1016/j.kint.2025.04.028","DOIUrl":"https://doi.org/10.1016/j.kint.2025.04.028","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":14.8,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SEN, SLANH, and SEEDO Consensus report on Obesity related kidney disease. Proposal for a new classification.","authors":"Jorge Rico-Fontalvo,Andreea Ciudin,Ricardo Correa-Rotter,Francisco J Díaz-Crespo,Carlos Bonanno,Albert Lecube,Rodrigo Daza-Arnedo,Enrique Morales,Borja Quiroga,Eduardo Lorca,Esteban Porrini,Miriam Machado,Vicente Sánchez Polo,Guillermo Álvarez,Fernanda Toniolo,María José Soler","doi":"10.1016/j.kint.2025.06.013","DOIUrl":"https://doi.org/10.1016/j.kint.2025.06.013","url":null,"abstract":"Obesity-related Chronic Kidney Disease (Ob-CKD) is an alteration that affects a wide variety of patients with chronic kidney disease at different levels: without ultrastructural lesions (hyperfiltration and/or albuminuria), with obesity-related glomerulopathy (glomerular hypertrophy, podocytopathy, matrix mesangial expansion, focal and segmental glomerulosclerosis, tubular-interstitial fibrosis, vascular lesions and tubular atrophy), associated with other kidney diseases, in CKD persons in dialysis programs as well as patients with transplanted kidneys. The S.E.N. (Sociedad Española de Nefrología), SLANH (Sociedad Latinoamericana de Nefrología e Hipertensión), and SEEDO (Sociedad Española para el Estudio de la Obesidad) Consensus report on Ob-CKD proposes a classification based on kidney alterations and CKD stage (either CKD, dialysis, or kidney transplant) with the clear aim to unify nomenclature and subsequently the management of persons with Ob-CKD. The document defines a classification of Ob-CKD. As seen with current times in terms of new strategies for Ob-CKD treatment, the consensus also recognizes that an effective management of obesity in persons with CKD, when available, should be treated by a multidisciplinary team that incorporates nutrition, physical activity, pharmacotherapy as well as bariatric surgery if indicated. In addition, the consensus also mentioned the new therapeutic approach with incretin-based therapies that has demonstrated to decrease body weight and have a beneficial effect on cardiorenal events and reduction in cardiovascular death in patients with obesity and CKD.","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"1 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic literature review and meta-analysis evaluated modifiable risk factors for the development of BK polyoma virus-associated complications.","authors":"Michael Eder, Alexander Kainz, Haris Omic, Christof Aigner, Dragan Copic, Camille N Kotton, Nassim Kamar, David Wojciechowski, Hans H Hirsch, Rainer Oberbauer","doi":"10.1016/j.kint.2025.06.014","DOIUrl":"10.1016/j.kint.2025.06.014","url":null,"abstract":"<p><strong>Background: </strong>BK polyomavirus-associated nephropathy (BKPyVAN) remains a significant cause of kidney graft injury. Several risk factors are suggested, mostly based on monocentric or retrospective studies. By performing a systematic literature review and comprehensive meta-analysis we sought to provide solid assumptions and test the reproducibility of known modifiable clinical risk factors for BKPyV.</p><p><strong>Methods: </strong>Literature search included Medline, Embase and Cochrane Register of Controlled Trials. Research question was defined with PICOTS framework. Pro- and retrospective clinical studies reporting BKPyV complications in adult kidney transplant recipients were included. Odds, hazard, or risk ratios were directly extracted or calculated. Endpoints were biopsy-proven-, presumptive BKPyVAN, BKPyV-DNAemia and events leading to treatment. Pooled risks were calculated with random effects models. Bias risks were assessed with QUIPS tools, funnel plots and I² statistics.</p><p><strong>Results: </strong>We identified 6,690 publications and included 165 encompassing 197,029 total patients. Twenty-nine studies were graded as high risk for bias. The number of included studies was highest for anti-thymocyte globulin vs. IL-2RA (78 studies), tacrolimus versus cyclosporine (54 studies), and ABO-incompatible transplantation (32 studies). Corticosteroids were significantly associated with three out of four endpoints, tacrolimus and anti-thymocyte globulin with two, tacrolimus levels, blood group ABO incompatibility transplantation, rituximab, mycophenolate mofetil, mTOR inhibitors and ureteral stents with one each.</p><p><strong>Conclusions: </strong>We were not able to identify a single independent risk factor for all endpoints, reflecting the complexity in predicting BKPyV-related complications in kidney transplant recipients. Rather than a single drug or procedure, insufficient net immune control over BKPyV replication in donor kidney may significantly promote BKPyV complications.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":14.8,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}